United Therapeutics (UTHR) Cash from Investing Activities (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Cash from Investing Activities data on file, last reported at $743.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 551.55% year-over-year to $743.7 million; the trailing twelve-month figure through Mar 2026 stood at $357.1 million (up 173.96% YoY), and the FY2025 full-year result was -$551.3 million, down 232.14% from the prior year.
• Cash from Investing Activities advanced to $743.7 million in Q1 2026, from -$227.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $743.7 million in Q1 2026 to a low of -$359.2 million in Q1 2022.
• A 5-year average of -$54.2 million and a median of -$164.7 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities tumbled 5601.59% in 2022 and jumped 551.55% in 2026, its largest moves.
• Tracing UTHR's Cash from Investing Activities over 5 years: stood at -$189.3 million in 2022, then jumped by 122.24% to $42.1 million in 2023, then slumped by 392.64% to -$123.2 million in 2024, then plunged by 84.74% to -$227.6 million in 2025, then surged by 426.76% to $743.7 million in 2026.
• Business Quant data shows UTHR's Cash from Investing Activities at $743.7 million in Q1 2026, -$227.6 million in Q4 2025, and $140.9 million in Q3 2025.